Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher J. Northfield is active.

Publication


Featured researches published by Christopher J. Northfield.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery of Cell-Active Phenyl-Imidazole Pin1 Inhibitors by Structure-Guided Fragment Evolution.

Andrew J. Potter; Victoria Oldfield; Claire L. Nunns; Christophe Fromont; Stuart Ray; Christopher J. Northfield; Christopher J. Bryant; Simon F. Scrace; David M. Robinson; Natalia Matossova; Lisa Baker; Pawel Dokurno; Allan Surgenor; Ben Davis; Christine M. Richardson; James B. Murray; Jonathan D. Moore

Pin1 is an emerging oncology target strongly implicated in Ras and ErbB2-mediated tumourigenesis. Pin1 isomerizes bonds linking phospho-serine/threonine moieties to proline enabling it to play a key role in proline-directed kinase signalling. Here we report a novel series of Pin1 inhibitors based on a phenyl imidazole acid core that contains sub-μM inhibitors. Compounds have been identified that block prostate cancer cell growth under conditions where Pin1 is essential.


Tetrahedron Letters | 1998

A facile and highly stereoselective approach to a polycyclic isoindolinone ring system via an N-acyliminium ion cyclization reaction

Steven M. Allin; Christopher J. Northfield; Michael I. Page; Alexandra M. Z. Slawin

A highly diastereoselective synthesis of chiral ring-fused isoindolinone products, the skeleton of which is common to many naturally occurring and biologically active compounds, is achieved in only two synthetic steps from readily available precursors via an N-acyliminium ion cyclization reaction of an isoindolinone substrate.


Tetrahedron Letters | 1997

A highly diastereoselective synthesis of tricyclic lactams and their application as novel N-acyl iminium ion precursors in the synthesis of isoindolinone derivatives

Steven M. Allin; Christopher J. Northfield; Michael I. Page; Alexandra M. Z. Slawin

Condensation of 2-formylbenzoic acid with α-amino alcohol substrates proceeds with extremely high diastereoselectivity to produce tricyclic γ-lactam products. The relative stereochemistry of the major diastereoisomer has been determined by X-ray crystal analysis and a mechanism suggested to explain the stereochemical outcome. Further, we report that this class of heterocycle can act as an N-acyl iminium ion precursor in the synthesis of substituted isoindolinone derivatives.


Bioorganic & Medicinal Chemistry Letters | 2000

Synthesis and antimicrobial activity of some isoindolin-1-ones derivatives

Jaco C. Breytenbach; Sandra van Dyk; Ilse van den Heever; Steven M. Allin; Claire C. Hodkinson; Christopher J. Northfield; Micheal I. Page

A range of N-substituted isoindolin-1-ones was prepared and their potential as novel antimicrobial agents was investigated. MIC values for active compounds were determined and reported.


Tetrahedron Letters | 1999

A highly diastereoselective synthesis of 3-substituted isoindolin-1-one dericatives

Steven M. Allin; Christopher J. Northfield; Michael I. Page; Alexandra M. Z. Slawin

A highly diastereoselective method for the synthesis of 3-substituted isoindolin-1-ones has been developed through application of a tricyclic lactam substrate as an N-acyliminium ion precursor. Ring-opening of the tricyclic lactam with triethylsilane as hydride source generates the targets with up to exclusive levels of diastereoselectivity. This approach compliments that reported in the preceding paper.


Tetrahedron Letters | 1999

A new approach to the synthesis of non-racemic isoindolin-1-one derivatives

Steven M. Allin; Christopher J. Northfield; Michael I. Page; Alexandra M. Z. Slawin

A new approach for the synthesis of non-racemic 3-substituted isoindolin-1-one targets has been developed through application of a tricyclic γ-lactam substrate as an N-acyliminium ion precursor.


Journal of Medicinal Chemistry | 2017

Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase.

Paul Brough; Lisa Baker; Simon Bedford; Kirsten Brown; Seema Chavda; Victoria Chell; Jalanie D’Alessandro; Nicholas Gareth Morse Davies; Ben Davis; Loic le Strat; Alba T. Macias; Daniel Maddox; Patrick C. Mahon; Andrew Massey; Natalia Matassova; Sean McKenna; Johannes W. G. Meissner; Jonathan D. Moore; James B. Murray; Christopher J. Northfield; Charles Parry; Rachel Parsons; Stephen D. Roughley; Terry Shaw; Heather Simmonite; Stephen Stokes; Allan Surgenor; Emma Stefaniak; Alan Duncan Robertson; Yikang Wang

Libraries of nonpurified resorcinol amide derivatives were screened by surface plasmon resonance (SPR) to determine the binding dissociation constant (off-rate, kd) for compounds binding to the pyruvate dehydrogenase kinase (PDHK) enzyme. Parallel off-rate measurements against HSP90 and application of structure-based drug design enabled rapid hit to lead progression in a program to identify pan-isoform ATP-competitive inhibitors of PDHK. Lead optimization identified selective sub-100-nM inhibitors of the enzyme which significantly reduced phosphorylation of the E1α subunit in the PC3 cancer cell line in vitro.


Journal of The Chemical Society-perkin Transactions 1 | 2000

Approaches to the synthesis of non-racemic 3-substituted isoindolinone derivatives

Steven M. Allin; Christopher J. Northfield; Michael I. Page; Alexandra M. Z. Slawin

New methodology for the synthesis of non-racemic isoindolinone targets has been developed through application of tricyclic γ-lactam substrates as N-acyliminium ion precursors in reactions with carbon and hydride nucleophiles. Removal of the phenylglycinol derived chiral auxiliary can be achieved without loss of stereochemical integrity at the newly created asymmetric centre, and we report a novel method for this key step using conc. sulfuric acid.


Archive | 2006

PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS

David Lee Walmsley; Martin J. Drysdale; Christopher J. Northfield; Christophe Fromont


Molecular Cancer Therapeutics | 2018

Abstract B163: Identification and preclinical characterisation of VER-250840, a potent, selective Chk1 inhibitor with in vivo oral single-agent antitumor activity

Joanne Wayne; Stephen Stokes; Nicolas Foloppe; Helen Browne; Teresa Brooks; Karen Benwell; Lisa Baker; Zoe Daniels; Andreá Fiumana; Christopher John Graham; Alba T. Macias; Daniel Maddox; Sean McKenna; Christopher J. Northfield; Stuart Ray; Heather Simmonite; Emma Stefaniak; Paul Webb; Mike Wood; Andrew Massey

Collaboration


Dive into the Christopher J. Northfield's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael I. Page

University of Huddersfield

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lisa Baker

Northwestern University

View shared research outputs
Top Co-Authors

Avatar

Allan Surgenor

University of Hertfordshire

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Brough

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ben Davis

Ludwig Institute for Cancer Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge